Assessment of the 4‐factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL studyFortunato Morabito, Massimo Gentile, Andrea Visentin et al.|American Journal of Hematology|2021Cited by 14
<scp><i>TP53</i></scp> disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia casesFortunato Morabito, Massimo Gentile, Giovanni Del Poeta et al.|American Journal of Hematology|2021Cited by 13
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximabMassimo Gentile, Fortunato Morabito, Enrica Antonia Martino et al.|Blood Cancer Journal|2020Cited by 12
Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia casesFortunato Morabito, Massimo Gentile, Giovanni Tripepi et al.|European Journal Of Haematology|2020Cited by 7
Effectiveness of ibrutinib as first‐line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab‐bendamustine: Results of study on 486 cases outside clinical trialsFortunato Morabito, Massimo Gentile, Giovanni Tripepi et al.|American Journal of Hematology|2021Cited by 3